Omnitarg (Breast Cancer) – Analysis and Forecasts to 2020
Summary
GlobalData’s pharmaceuticals report, “Omnitarg (Breast Cancer) – Analysis and Forecasts to 2020” provides Omnitarg sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, and EU5 (six major markets)
- Analysis and review of Omnitarg including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Omnitarg including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2012-2020 for Omnitarg in the six major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Keywords
Omnitarg, Breast Cancer, Pertuzumab, Sales forecast, HER 2 Inhibitor, Phase III, Phase 3, Pipeline, Competitors to Arimidex, Tykerb and Neratinib, Roche
Pathology Industry in Japan
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Etiology and Risk Factors 7
2.3.1 Age and Gender 7
2.3.2 Genetic Inheritance 7
2.3.3 Hormone Replacement Therapy 7
2.3.4 Radiation 7
2.3.5 Obesity 7
2.3.6 Alcohol Consumption 7
2.3.7 Late Child Birth 7
2.3.8 Use of Birth Control Pills 7
2.4 GlobalData Report Guidance 8
3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 Breast Cancer: Most Frequent Cancer in Women 10
3.3.2 Increasing Breast Cancer Incidence Rate 10
3.3.3 Decreasing Breast Cancer Mortality Rate 12
3.3.4 High Survival Rates of Breast Cancer 14
4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15
5 Predictive Biomarker in the Treatment of Breast Cancer 17
6 Treatment Options of Breast Cancer 19
6.1 Stage 0 Breast Cancer 19
6.2 Early Stage Breast Cancer (Excluding Stage 0) 20
6.3 Metastatic Breast Cancer (MBC) 22
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 22
6.3.2 Cytotoxic Chemotherapy 24
6.3.3 Management of Patients with HER-2 Positive Patients 26
7 Omnitarg 28
7.1 Introduction 28
7.2 Mechanism of Action 28
7.3 Clinical Studies 28
7.4 Factors Affecting Sales of Omnitarg 28
7.4.1 Limited use as Combination Therapy 28
7.4.2 Good Efficacy Profile 29
7.4.3 Combination with T-DM1 29
7.5 Drug Evaluation 29
7.5.1 Drug Risk Benefit Score 29
7.5.2 Intensity of Competition 30
7.6 Sales Forecasts 30
7.6.1 Target Patient Pool of Omnitarg 30
7.6.2 Market Penetration 31
7.6.3 Dosing 31
7.6.4 Annual Cost of Therapy 32
7.6.5 Sales Projections of Omnitarg 32
8 Appendix 41
8.1 Market Definitions 41
8.2 Abbreviations 41
8.3 Research Methodology 41
8.3.1 Coverage 41
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of Patients Approved to Take the Drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 43
8.7 Sources 44
List of Tables
Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Five-Year Relative Survival Rates, 2005, By Stages 14
Table 3: Drug Risk Benefit Score of Omnitarg 29
Table 4: Comparison with Major Competitors 30
Table 5: Omnitarg, Breast Cancer, Global, Sales Forecasts ($m), 2012–2020 32
Table 6: Omnitarg, Breast Cancer, The US, Sales Forecasts ($m), 2012–2020 33
Table 7: Omnitarg, Breast Cancer, The UK, Sales Forecasts ($m), 2012–2020 34
Table 8: Omnitarg, Breast Cancer, France, Sales Forecasts ($m), 2012–2020 35
Table 9: Omnitarg, Breast Cancer, Germany, Sales Forecasts ($m), 2012–2020 36
Table 10: Omnitarg, Breast Cancer, Italy, Sales Forecasts ($m), 2012–2020 37
Table 11: Omnitarg, Breast Cancer, Spain, Sales Forecasts ($m), 2012–2020 38
Table 12: Omnitarg, Breast Cancer, Japan, Sales Forecasts ($m), 2013–2020 39
List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 9
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 10: Broad Classification of Breast Cancer, By Type 15
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 12: Classification of Invasive Breast Cancer, By Stages 16
Figure 13: Classification of Invasive Breast Cancer, By Treatment 16
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 18
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 18
Figure 17: Treatment Options, DCIS Breast Cancer 19
Figure 18: Treatment Options, LCIS Breast Cancer 20
Figure 19: Classification of Stages I, II and IIIA 20
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26
Figure 27:Drug Model Diagram of Omnitarg 31
Figure 28: Omnitarg, Breast Cancer, Global, Sales Forecasts ($m), 2012–2020 32
Figure 29: Omnitarg, Breast Cancer, The US, Sales Forecasts ($m), 2012–2020 33
Figure 30: Omnitarg, Breast Cancer, The UK, Sales Forecasts ($m), 2012–2020 34
Figure 31: Omnitarg, Breast Cancer, France, Sales Forecasts ($m), 2012–2020 35
Figure 32: Omnitarg, Breast Cancer, Germany, Sales Forecasts ($m), 2012–2020 36
Figure 33: Omnitarg, Breast Cancer, Italy, Sales Forecasts ($m), 2012–2020 37
Figure 34: Omnitarg, Breast Cancer, Spain, Sales Forecasts ($m), 2012–2020 38
Figure 35: Omnitarg, Breast Cancer, Japan, Sales Forecasts ($m), 2013–2020 39
Figure 36 : Omnitarg, Breast Cancer, Global, Sales Distribution, By Country (%), 2020 40
Figure 37: Patients Approved for the Drug 42
